Patent Application
20080033005
The present invention relates to methods of treating multiple sclerosis. In particular, the present invention relates to the treatment of multiple sclerosis through the protection of the central nervous system on a cellular level through the inhibition of demyelination of neurons and/or oligodendrocytes afflicted with the disease with certain compounds disclosed herein, their isomers, racemates, enantiomers, their salts, and medicaments containing them.
Multiple sclerosis (MS) is an autoimmune disease that leads to a loss of CNS (central nervous system) myelin, oligodendrocyte cell death and axonal destruction, causing severe functional deficits. MS occurs at a 2-3 times higher incidence in women than men (Duquette, et al., 1992. Can. J. Neurol. Sci. 19: 466-71.) and estrogen reduces disease severity during the second and third trimesters of pregnancy (Confavreux et al., 1998. N Eng J Med 339: 285-291), whereas the clinical symptoms of MS have been reported to exacerbate after delivery (Evron et al., 1984. Am. J. Reprod. Immunol. 5:109-113; Mertin and Rumjanek 1985. J. Neurol Sci. 68:15-24; Grossman, 1989. J. Steroid Biochem. 34: 241-245; Confavreux et al., 1998. N. Engl. J. Med. 339: 285-291). Treatment with estradiol decreases gadolinium-enhancing lesions and MRI volume (Voskuhl and Palaszynski, 2001. Neuroscientist. 7(3): 258-270; Sicotte et al., 2002. Ann Neurol. 52: 421-428). Furthermore, estrogens cause immune response shifts, amelioration of clinical symptoms and enhanced myelin formation in rodent EAE (experimental allergic encephalomyelitis) (Curry and Heim 1966. Nature 81: 1263-1272; Kim et al., 1999. Neurology. 52: 1230-1238; Ito et al., 2002. Clin Immunol. 102(3): 275-282). Estrogen has been reported to protect oligodendrocytes from cytotoxicity induced cell death (Takao et al, 2004. J Neurochem. 89: 660-673) and 17β-estradiol (E2) has been reported to hasten the elaboration of multiple, interconnecting processes on oligodendrocytes (Zhang et al., 2004. J Neurochem 89: 674-684).
There is increasing evidence that estrogen plays a direct protective role in response to degenerative disease and injury by enhancing cell survival, axonal sprouting, regenerative responses, synaptic transmission, and neurogenesis. In the CNS, there is increased synthesis of estrogen and enhanced expression of the estrogen receptors at sites of injury (Garcia-Segura et al., 2001. Prog. in Neurobiol. 63: 29-60.) and estrogen-mediated cellular protection has been demonstrated in a number of in vitro models of neurodegeneration, including β-amyloid induced cytotoxic, excitotoxicity, and oxidative stress (Behl et al., 1995. Biochem. Biophys. Res. Commun. 216,473-482; Goodman et al., 1996. J. Neurochem. 66:1836-1844; Green et al., 1997. J. Neurosci. 17: 511-515; Behl et al., 1999. Trends Pharmacol. Sci. 20: 441-444). Recent clinical studies suggest that estrogen replacement therapy may also decrease the risk and delay the onset and progression of Alzheimer's disease and schizophrenia. (For a review see Garcia-Segura et al., 2001. Prog. in Neurobiol. 63: 29-60.) E2, a lipophilic hormone that can cross the blood-brain barrier, and metabolically sustain and maintain those sections of the brain responsible for arousal, attention, mood, and cognition (Lee and McEwan, 2001. Annu. Rev. Pharmacol. & Toxicol. 41: 569-591.). In addition, both natural estrogens and synthetic selective estrogen receptor modulators (SERMs), such as tamoxifen, decrease neuronal damage caused by ischemic stroke, while either E2 or raloxifene protect neurons against 1-methly-4-phenyl-1,2,3,6 tetrahydropyridine-induced toxicity (Callier, et al., 2001. Synapse 41: 131-138; Dhandapani and Brann, 2003. Endocrine 21: 59-66).
The neuroprotective effects of estrogen are mediated through the modulation of bcl-2 expression, the activation of cAMP and mitogen-activated kinase signaling pathways, the modulation of intracellular calcium homeostasis, the enhancement of antioxidant activity, and/or activation of estrogen receptors (ER) that can act as hormone-regulated transcription factors (Mangelsdorf, et al., 1995. Cell 83: 835-839; Katzenellenbogen, et al., 1996. Mol. Endocrinol. 10: 119-131; Singer et al., 1996. Neurosci. Lett. 212: 13-16; Singer et al., 1998. Neuroreport 9: 2565-2568; Singer et al., 1999. Neurosci. Left. 212: 13-16; Weaver et al., 1997. . Brain Res. 761: 338-341; Watters and Dorsa, 1998. J. Neurosci. 18: 6672-6680; Singh et al., 1999. J. Neurosci. 19: 1179-1188; Alkayed et al., 2001. J. Neurosci. 21: 7543-7550; Garcia-Segura et al., 2001. Prog. in Neurobiol. 63: 29-60). Two estrogen receptors that have been characterized, ERα and ERβ, belong to the class I hormone receptor family that function as nuclear transcription factors. ERα and ERβ (in the form of mRNA or protein) are expressed in neural cell types including Schwann cells, the myelin forming cells of the peripheral nervous system, and CNS neurons, astrocytes and oligodendrocytes (Miranda and Toran-Allerand, 1992; Santagati, et al., 1994; Kuiper, et al., 1996; Mosselman, et al., 1996; Thi et al. 1998; Platania, et al., 2003). In oligodendrocytes, the myelin forming cells of the CNS that are lost in MS, ERα has been reported to be nuclear, whereas ERβ is cytoplasmic, in vivo immunoreactivity being readily detectable in the cytoplasm and myelin sheaths (Zhang et al., 2004. J Neurochem 89: 674-684). Recently, Arvanitis at al., 2004 (J Neurosci Res. 75: 603-613) have reported an ER with similarities to ERβ in isolated CNS myelin, the myelin sheath of spinal cord and brain sections and the oligodendrocyte plasma membrane.
Mimicking and/or enhancing the beneficial effects of estrogen in MS by means of small molecules that are ligands at ERA, or compounds that preferentially mimic the effects of estrogen at sites other than the classical ERα is likely to have advantages for the treatment of MS in that the small molecules would be devoid of the untoward “hormonal” effects of estrogen which are mediated by ERα. These other ER sites may include the recently identified ER-X, which has been identified in neurons and is developmentally regulated (Toran-Allerand 2004. Endocrinology 145:1069-1074), or GPR30, which allows estrogen to trigger different pathways that integrate cell surface signaling with gene transcription (Kanda and Watanabe 2003. J Invest Derm 121: 771-780).
These compounds may also be used to treat or prevent the development of other demyelinating diseases, including Charcot-Marie-Tooth disease, Pelizaeus-Merzbacher disease, encephalomyelitis, neuromyelitis optica, adrenoleukodystrophy, Guillain-Barre syndrome, and disorders in which myelin-forming glial cells (oligodendrocytes or Schwann cells) are damaged, including spinal cord injury, neuropathies and nerve injury.
Certain compounds, including 5,6-dihydro-3,9-dihydroxyindolo[2,1-a-isoquinolin-1,2-yl)[4-[2-(1-piperidinyl)ethoxy]phenyl]-ethanone and arzoxifen, are useful for the metabolic protection and maintenance of oligodendrocytes and neurons of multiple sclerosis patients.
The present invention comprises the treatment of multiple sclerosis through the protection of the central nervous system on a cellular level through the inhibition of de-myelination of neurons and/or oligodendrocytes afflicted with the disease. This therapeutic endeavor is achieved through the administration of one of two compounds, 5,6-dihydro-3,9-dihydroxyindolo[2,1-a-isoquinolin-1,2-yl)[4-[2-(1-piperidinyl)ethoxy]phenyl]-methanone and arzoxifen, their acid-addition salts of inorganic or organic acids and formulations comprising them.
These compounds, 5,6-dihydro-3,9-dihydroxyindolo[2,1-a-isoquinolin-1,2-yl)[4-[2-(1-piperidinyl)ethoxy]phenyl]-methanone and arzoxifen, contain one or more asymmetric centers and thereby have isomeric forms and these isomers and mixtures thereof also fall within the penumbra of the claimed invention as well as the racemates and the enantiomers thereof. Structurally, the compounds useful in the claimed methods of treatment are as follows:
A) 5,6-dihydro-3,9-dihydroxyindolo[2,1-a]isoquinolin-12-yl)[4-[2-(1-piperidinyl)ethoxy]phenyl]-methanone
B) Arzoxifen
The compounds may be formulated as described herein below with excipients, diluents, solvents, binders, lubricants, carriers and other traditional pharmaceutically acceptable components known in the art.
As set forth below, the terms used in this specification have their respective meanings defined as follows.
The selection of the appropriate salt may be important so that the ester is not hydrolyzed. The selection criteria for the appropriate salt will be known to one skilled in the art.
In treating a patient afflicted with a condition described above, a selected compound can be administered in any form or mode which makes the compound bioavailable in therapeutically effective amounts, including orally, sublingually, buccally, subcutaneously, intramuscularly, intravenously, transdermally, intranasally, rectally, topically, and the like. One skilled in the art of preparing formulations can determine the proper form and mode of administration depending upon the particular characteristics of the compound selected for the condition or disease to be treated, the stage of the disease, the condition of the patient and other relevant circumstances. For example, see Remington's Pharmaceutical Sciences, 18th Edition, Mack Publishing Co. (1990), incorporated herein by reference.
The compositions of the present invention may be administered orally, for example, in the form of tablets, troches, capsules, elixirs, suspensions, solutions, syrups, wafers, chewing gums and the like and may contain one or more of the following adjuvants: binders such as microcrystalline cellulose, gum tragacanth or gelatin; excipients such as starch or lactose, disintegrating agents such as alginic acid, Primogel, corn starch and the like; lubricants such as magnesium stearate or Sterotex; glidants such as colloidal silicon dioxide; and sweetening agents such as sucrose or saccharin may be added or a flavoring agent such as peppermint, methyl salicylate or orange flavoring. When the dosage unit form is a capsule, it may contain, in addition to materials of the above type, a liquid carrier such as polyethylene glycol or a fatty oil. Other dosage unit forms may contain other various materials, which modify the physical form of the dosage unit, for example, as coatings. Thus, tablets or pills may be coated with sugar, shellac, or other enteric coating agents. A syrup may contain, in addition to the present compounds, sucrose as a sweetening agent and certain preservatives, dyes and colorings and flavors.
The compounds of this invention may also be administered topically, and when done so the carrier may suitably comprise a solution, ointment or gel base. The base, for example, may comprise one or more of petrolatum, lanolin, polyethylene glycols, bee wax, mineral oil, diluents such as water and alcohol, and emulsifiers and stabilizers.
The solutions or suspensions may also include one or more of the following adjuvants: sterile diluents such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl paraben; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylene diaminetetraacetic acid; buffers such as acetates, citrates or phosphates and agents for the adjustment of tonicity such as sodium chloride or dextrose. The parenteral preparation can be enclosed in ampules, disposable syringes or multiple dose vials.
The dosage range at which compounds of the invention exhibit their ability to act therapeutically can vary depending upon the particular compound, the severity of the condition, the patient, the formulation, other underlying disease states that the patient is suffering from, and other medications that may be concurrently administered to the patient. Generally, the compound of Formula I will exhibit their therapeutic activities at dosages of between about 0.001 mg/kg of patient body weight/day to about 100 mg/kg of patient body weight/day.
The contents of all publications and patents discussed herein are hereby incorporated herein by reference.
It will be appreciated that every suitable combination of the respective elements of the present invention may be interchanged with one or more of other similar, suitable components known in the art and changed in minor, non-functional respects. These additional embodiments of the invention are also regarded as falling within the scope of the claims herein. The examples detailed below are provided to better describe and more specifically set forth the elements and mechanics/operation of the present invention with reference to the drawing, but for obvious reasons cannot describe all of them. It is to be recognized that the examples therefore are for illustrative purposes only however, and should not be interpreted as limiting the spirit and scope of the invention as later recited by the claims that follow.
Neuroprotection Assay
Cells from a human neuroblastoma cell line, SK-N-SH cells, were plated at 50,000 cells/well in Costar Biocoat 96-well poly-D-lysine coated plates in EMEM (Minimum Essential Medium Eagle with Earle's salts) containing penicillin/streptomycin, L-glutamine, sodium pyruvate, non-essential amino acids and sodium bicarbonate. Cells were grown overnight in a 37° C. incubator under 5% CO2. The next day, the medium was removed and replaced with fresh medium. Cells were pretreated with Serms for 1 hour, and SIN-1 (3-morpholinosydnonimine, which produces peroxynitrite) was added to give a final concentration of 2 or 10 mM. After 24 hours, the medium was removed and assayed for LDH activity using the Promega cytotox 96 kit (catalog# G1780). Results were calculated as percent protection against SIN-1 toxicity.
ERK1/2 Westerns
SK-N-SH cells were plated at 2×106 cells/well in 6-well polystyrene culture plates, in 2 ml EMEM containing penicillin/streptomycin, L-glutamine, sodium pyruvate, non-essential amino acids and sodium bicarbonate. Cells were grown overnight at 37° C. under 5% CO2.
The next day, 200 μl medium was removed and cells were dosed with 200 μl compound made up to 10 times the final concentration in medium. After incubation for the appropriate time, medium was aspirated off and cells washed twice with cold PBS. They were then lysed with 100 μl RIPA buffer containing protease and phosphatase inhibitors.
For westerns, 20 μg protein was denatured at 95° C. in Laemmli sample buffer containing beta-mercaptoethanol, then loaded onto 4-20% gradient Tris Glycine SDS gels and electrophoresed at 70 volts until completed. Proteins were transferred to nitrocellulose membranes and probed for phospho-ERK1/2 and total ERK1/2 using the appropriate antibodies. Bands were detected using ECL western blotting chemiluminescent substrate. For phospho-ERK ELISA's, the ELISA kit from Assay Designs was used.
Bcl-2 Luciferase
SK-N-MC Bcl-2 (neo) clone 218 was plated at 25,000 cells per well in Packard View plates in phenol Red free EMEM containing penicillin/streptomycin, L-glutamine, sodium pyruvate, non-essential amino acids, sodium bicarbonate and 200 ug/ml G418. Cells were grown overnight in a 37° C. incubator under 5% CO2.
On day 2, medium was removed and replaced with serum-free EMEM containing ITS supplement (BD Biosciences # 35 4352). Medium was changed again on days 3 and 4; on day 4 cells were dosed with compounds, in a final volume of 100 μl. Twenty-four hours after dosing, 100 μl SteadyGlo (Promega# E2510) was added and luciferase measured in a Packard Topcount liquid scintillation counter.
Oligodendrocyte Toxicity Assay
Primary rat oligodendrocyte progenitor cells were obtained from the cerebra of 2-3 day old postnatal rats (Sprague Dawley). The meninges were removed and tissue was mechanically dissociated. Cells were plated on T75 flasks and fed with DMEM+10% FBS.
Enriched OLPs were collected by mechanical separation from the astrocytic monolayer and were expanded in serum free media (SFM) supplemented with the mitogens, PDGF-AA (10 ng/ml) and FGF-2 (10 ng/ml).
To generate mature oligodendrocytes, progenitor cells were switched to SFM supplemented with IGF-1 (10 ng/ml) 24 hours after plating and cells were grown under these conditions for 7 days prior to experimental assays.
Cells were plated in 96-well plates, 10,000 per well. Medium was changed to fresh medium and cells were pretreated with compounds for 1 hour. Toxins were added to give the following final concentrations:
After 24 hours, medium was removed and assayed for LDH activity using the Promega cytotox 96 kit (catalog# G1780). Results were calculated as percent protection against toxin-induced toxicity.
These compounds have been assessed for their efficacy in neuroprotection against cell death produced by toxic agents such as SIN-1 (3-morpholino-sydnonimine, producing peroxynitrite), C2 ceramide, camptothecin, staurosporine, SNAP (S-nitroso-N-acetylpenicillamine, producing nitric oxide), and pyrogallol (producing superoxide anion). The target cells assessed in vitro are: human neuroblastoma cell lines [SK-N-SH, SH-SY5Y], and primary cultures of rodent oligodendrocyte progenitors and their mature counterparts. Protection by these serm-like compounds have been compared to 17-β-estradiol and tamoxifene. (See Table 1 below) The mechanism of action of this neuroprotection has been investigated with respect to the use of a classical nuclear (genomic) ERα or β and an assessment of the role for phosphorylation of MAPK p40/p42 (ERK1/2).
Pharmacological Composition
Both compounds tested appear to protect neurons and oligodendrocytes. This appears to be mediated by the upregulation of ERK1/2 phosphorylation, which is confirmed by inhibition of the neuroprotection by U-0126, a MEK inhibitor, specific for the ERK pathway.
This application is a continuation of International Patent Application No. PCT/US2005/045295 filed on Dec. 14, 2005 which is incorporated herein by reference in its entirety which also claims the benefit of priority of U.S. Provisional Patent Application No. 60/640,926 filed on Dec. 31, 2004.
| Number | Date | Country | |
|---|---|---|---|
| 60640926 | Dec 2004 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | PCT/US05/45295 | Dec 2005 | US |
| Child | 11764259 | Jun 2007 | US |
